This startup is developing protein therapeutics specifically designed to treat severe allergic diseases by targeting and modulating immune responses. Their approach aims to provide effective treatment options for patients who suffer from debilitating allergic reactions.
Funding
$79.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Severe allergic diseases can cause debilitating reactions, and current treatment options may not be fully effective for all patients. Modulating immune responses to alleviate these allergic reactions remains a significant challenge.
Solution
Excellergy is developing protein therapeutics engineered to target and modulate immune responses, offering a novel approach to treating severe allergic diseases. Their therapies aim to provide effective treatment options for patients suffering from debilitating allergic reactions by specifically addressing the underlying immunological mechanisms. By precisely targeting the immune pathways involved in allergic responses, Excellergy seeks to develop treatments that can reduce the severity and frequency of allergic reactions, improving the quality of life for affected individuals. The company's focus is on creating innovative protein-based therapies that offer a more targeted and effective approach to managing severe allergies.
Target Audience
The primary target audience includes individuals suffering from severe allergic diseases and the healthcare professionals who treat them.
Features
- Protein therapeutics designed to modulate immune responses
- Targeted approach to treat severe allergic diseases